Evidence map›Paper›PMID 42365354›Full record

ArticleBiomarker research2026

CD163

Mengjia Li, Yaomei Wang, Hong Huang, Hao Sun, Mengya Gao, Mingxia Sun, Xudong Li, Zexing Liu, Donghao Liu, Meimei Yan and 26 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomarker research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

Mengjia Li *Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450000, China.
Yaomei Wang *Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, 450008, China.
Hong Huang *Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450000, China.
Hao Sun *Department of Radiotherapy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450000, China.
Mengya Gao *Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, 450008, China.
Mingxia SunSchool of Public Health, Zhengzhou University, Zhengzhou, Henan, 450000, China.
Xudong LiDepartment of Hematology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, 450008, China.
Zexing LiuDepartment of Research and Foreign Affairs, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, China.
Donghao LiuSchool of Life Science, Zhengzhou University, Zhengzhou, Henan, 450000, China.
Meimei YanDepartment of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, China.
Zhenghua HuangDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450000, China.
Zhen ZhangDepartment of Abdominal and Pelvic Tumor Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450000, China.
Yuhan HuDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450000, China.
Bozheng WangDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450000, China.
Yiwei ZhouDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450000, China.
Siyue LiDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450000, China.
Yu AnDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450000, China.
Miao LiuDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450000, China.
Yupeng LiuDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450000, China.
Fengcai GaoDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450000, China.
Fangfang GeDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450000, China.
Wenjuan FanDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450000, China.
Hao WangSchool of Public Health, Zhengzhou University, Zhengzhou, Henan, 450000, China.
Xing LiSchool of Public Health, Zhengzhou University, Zhengzhou, Henan, 450000, China.
Fang WangDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450000, China.
Guomei FuDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450000, China.
Shiyu ZuoDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450000, China.
Binglei ZhangDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450000, China.
Jinxin MiaoAcademy of Chinese Medicine Science, Henan University of Chinese Medicine, Zhengzhou, Henan, China.
Chong WangDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450000, China.
Yongping SongDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450000, China.
Xiuli AnLaboratory of Membrane Biology, New York Blood Center, 310 East, 67th Street, New York, NY, 10065, USA.
Weijie CaoDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450000, China. caoweijie2003@126.com.
Linping XuDepartment of Research and Foreign Affairs, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, China. zlyyxulinping1475@zzu.edu.cn.
Wei LiInstitute of Infection and Immunity, Henan Academy of Innovations in Medical Science, Zhengzhou, Henan, 450007, China. zlyylw3028@zzu.edu.cn.
Zhilei BianDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450000, China. bianzhilei@zzu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlucocorticoids(GCs) are widely used to treat erythropoietin-resistant anemias, yet the precise mechanisms underlying their erythropoiesis-promoting effects remain incompletely understood.

methodsThis study used single-cell RNA sequencing, ATAC-seq, ChIP-seq, RNA-seq,quantitative PCR (qPCR), enzyme-linked immunosorbent assay (ELISA) and flow cytometry in vivo models (AIHA patients, CD163

resultsGC promote erythropoiesis by regulating CD163-mediated EBI formation and modulating iron metabolism within EBI macrophages, a phenomenon conserved across humans, rats, and mice. We demonstrated that CD163

conclusionsCD163⁺macrophages support GC-induced erythropoiesis by coordinating erythroblastic island formation and iron metabolism. These findings uncover a previously unrecognized GC-CD163-EBI axis that governs erythropoiesis and highlight the potential of targeting EBI macrophage function as a novel therapeutic strategy for anemia.

Indexed as

AIHACD163EBI macrophagesErythropoiesisGlucocorticoidsIron metabolism

Identifiers

PMID42365354
PMCPMC13330286

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.